首页> The Journal of urology> Long-Term Outcomes of Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma With UGN-101, a Mitomycin Reverse Thermal Gel.

Long-Term Outcomes of Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma With UGN-101, a Mitomycin Reverse Thermal Gel.

导出 OA

翻译打印收藏纠错

第一作者： Phillip M,Pierorazio

第一单位： Section of Urology, Department of Surgery, The University of Pennsylvania, Philadelphia, Pennsylvania.

作者： Phillip M,Pierorazio ^[1] ; Nir,Kleinmann ^[2] ; Ahmad,Shabsigh ^[3] ; Brian,Hu ^[4] ; Jay D,Raman ^[5] ; Hristos,Kaimakliotis ^[6] ; Alexander,Sankin ^[7] ; Nirmish,Singla ^[8] ; Andrew,Meads ^[9] ; Brent,Burger ^[9] ; Sunil,Raju ^[9] ; Michael J,Louie ^[9] ; Karim,Chamie ^[10] ; Alon,Weizer ^[11] ; Mark,Schoenberg ^[12]

作者单位： Section of Urology, Department of Surgery, The University of Pennsylvania, Philadelphia, Pennsylvania. ^[1] Department of Urology, Sheba Medical Center, Ramat Gan, Israel. ^[2] Department of Urology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio. ^[3] Department of Urology, Loma Linda University, Loma Linda, California. ^[4] Department of Urology, Milton S. Hershey Medical Center Penn State Health, Hershey, Pennsylvania. ^[5] Department of Urology, Indiana University School of Medicine, Indianapolis, Indiana. ^[6] Department of Urology, Albert Einstein College of Medicine, Bronx, New York. ^[7] The Brady Urological Institute, The Johns Hopkins University, Baltimore, Maryland. ^[8] Urogen Pharma, Princeton, New Jersey. ^[9] Department of Urology, University of California Los Angeles, Los Angeles, California. ^[10] Department of Urology, Mount Sinai Medical Center Division of Columbia University, Miami Beach, Florida. ^[11] Department of Urology, Albert Einstein College of Medicine, Bronx, New York.;Urogen Pharma, Princeton, New Jersey. ^[12]

关键词 carcinoma clinical trial mitomycin transitional cell